Designed With
Children in Mind
Nerivio is the only preventive migraine therapy and the first non-drug acute treatment FDA-approved for children aged 8-11. It is a pill-free, needle-free, non-disruptive prescribed treatment of migraine that is proven to empower children and teens to consistently and effectively manage migraine, giving them more control over their daily lives.
Preventing Chronification:
The Role of Early, Safe, and Effective Migraine Care in Children and Adolescents
Treating migraine effectively at an early age is crucial to avoid long-term complications and possibility for chronification in the future.1 Yet treatment options for children and adolesents are limited; many medications haven’t been tested for youth or may cause side effects that make it difficult to stay consistent with treatment.2
The Nerivio REN wearable meets this need by offering both preventive and acute migraine treatment through non-painful and safe stimulation. Nerivio harnesses the brain’s natural ability to control migraine pain and symptoms—all without systemic side effects or sedation.
The Limitations of Pharmacological Migraine Treatment in Children and Adolescents
Adequate treatment during childhood may prevent chronic or refractory migraine in adulthood1. But, many children don’t like to swallow pills and fear injections. Others have difficulties sticking to their pharmacological treatment plans. In some cases, medication treatment may be delayed or even stopped due to unpleasant side effects, dosing issues, or rebound headaches3.
A survey study found that the REN wearable empowers students to manage migraine attacks effectively, independently, and discreetly at school, significantly increasing in-school treatment rates and reducing barriers such as trips to the nurse’s office4.
Doctors’ Recommendations
“A large study of many patients over a lengthy period of time and multiple treatments, reinforces that REN [Nerivio] provides a safe, efficacious and stable treatment for acute migraine, both as a standalone and as an adjunct therapy."
“Chronic migraine patients experience more frequent and severe attacks than episodic migraine patients. Non-pharmacological interventions such as REN [Nerivio] help meet this need by providing a drug free treatment option.”
“Research shows this [REN, Nerivio] to be comparable with triptans. Pain relief at 2 hours was 67%, which is better than with many triptans.”
“With Nerivio, my patients have had a life-changing quality of life. Nerivio is not a want - it’s a need. This safe treatment for migraine is a vital breakthrough. It is my responsibility to let colleagues and patients know about this important therapy.”
Clinical Data
Sources
- Charles, J.A., Peterlin, B.L., Rapoport, A.M. et al. Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification. J Headache Pain 10, 227–233 (2009). Link
- Freitag, Frederick & Schloemer, Fallon. (2016). Recent developments in the treatment of migraine in children and adolescents. Journal of Headache & Pain Management. 1. 10.4172/2472-1913.100009.
- Taddeo D, Egedy M, Frappier JY. Adherence to treatment in adolescents. Paediatr Child Health. 2008;13(1):19-24. doi:10.1093/pch/13.1.19https://pmc.ncbi.nlm.nih.gov/articles/PMC2528818/
- Hershey AD, Shmuely S, Stark-Inbar A, Asmar Y, Ironi A, Strong E, Kabbouche M. Patterns, Barriers, and Preferences of Treating Migraine Within the School Setting: A Survey Study of Students. Children. 2024; 11(11):1286. https://doi.org/10.3390/children11111286